Digital therapeutics 2023: Swing and trial partner Curavit kick off fibromyalgia study
After the boom-and-bust cycling in digital therapeutics over the past few years, digital health providers are looking for 2023 to be a stabilizing year. Two of those companies are digital therapeutics developer Swing Therapeutics and all-virtual CRO Curavit Clinical Research.
The pair are currently enrolling a trial for Swing’s Stanza, a prescription smartphone DTx for fibromyalgia. The cognitive behavioral therapy treatment, which received a breakthrough device designation from the FDA in 2021, became available for patients in September, alongside the formal clinical trial which will finish enrollment soon with the study set to complete in the third quarter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.